Determination of Risk Factors Associated with the Failure of 12 Weeks of Direct-Acting Antiviral Therapy in Patients with Hepatitis C: A Prospective Study
Table 4
Regression coefficients and odds ratios (and 95% CIs) for risk factors associated with treatment failure after 12 weeks of DAA therapy in HCV patients ().
Independent variable
Slope
SE
OR (95% CI)
Intercept
-8.80
2.84
0.002
0.01 (0.01, 0.03)
Cirrhosis
2.28
0.67
0.001
9.72 (2.85, 39.28)
Genotype 2
0.96
0.85
0.262
2.6 (0.49, 14.29)
Genotype 3
-0.56
0.96
0.559
0.58 (0.09, 3.81)
Genotype 6
-1.17
0.82
0.053
0.32 (0.06, 0.87)
Baseline AST
0.03
0.01
0.003
1.03 (1.02, 1.05)
Baseline ALP
0.02
0.01
0.037
1.02 (1.01, 1.03)
Baseline hemoglobin
-0.05
0.02
0.003
0.96 (0.93, 0.99)
FIB-4
0.61
0.18
0.001
1.83 (1.36, 2.67)
Baseline viral load (log10 IU/ml)
0.88
0.26
0.001
2.4 (1.52, 4.17)
RVR
3.95
1.25
0.002
51.54 (6.39, 139.82)
RVR, rapid virological response; AST: aspartate aminotransferase; ALT: alanine transaminase; FIB-4: fibrosis index based on four factors.